AG
Sponsors
Judith Dixon-Hughes, Sun Yat-sen University, Tianjin Medical University Cancer Institute and Hospital, Zhejiang Provincial People's Hospital, Jin Xu
Conditions
Neoplasms PancreaticPancreatic CancerPancreatic Cancer MetastaticPancreatic Cancer Non-resectablePancreatic Cancer ResectablePancreatic Neoplasms
Phase 2
PRIMUS002: Looking at 2 Neo-adjuvant Treatment Regimens for Resectable and Borderline Resectable Pancreatic Cancer
TerminatedNCT04176952
Start: 2019-03-05End: 2021-08-19Updated: 2022-05-24
Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer
Active, not recruitingNCT05481476
Start: 2022-12-12End: 2026-12-31Target: 32Updated: 2025-09-04
Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis
NCT06405685
Start: 2023-04-27End: 2025-10-30Target: 30Updated: 2024-05-08
Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer
RecruitingNCT06722911
Start: 2024-11-15End: 2028-09-30Target: 57Updated: 2024-12-09
Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
Not yet recruitingNCT06916975
Start: 2025-04-15End: 2028-12-01Target: 46Updated: 2025-04-08
Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic Cancer
Not yet recruitingNCT07814859
Start: 2026-08-31End: 2029-08-31Target: 88Updated: 2026-09-11